ES2600827A8 - Formas cristalinas de bilastina y procedimientos para su preparación - Google Patents
Formas cristalinas de bilastina y procedimientos para su preparación Download PDFInfo
- Publication number
- ES2600827A8 ES2600827A8 ES201690068A ES201690068A ES2600827A8 ES 2600827 A8 ES2600827 A8 ES 2600827A8 ES 201690068 A ES201690068 A ES 201690068A ES 201690068 A ES201690068 A ES 201690068A ES 2600827 A8 ES2600827 A8 ES 2600827A8
- Authority
- ES
- Spain
- Prior art keywords
- bilastine
- preparation
- crystalline forms
- procedures
- relates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Formas cristalinas de bilastina y procedimientos para su preparación.#La presente invención se refiere a nuevas formas cristalina Alfa y Eta del ácido 4-[2-[4-[1-(2-etoxietil)-1H-bencimidazol-2-il]-1-piperidinil)etil]-{al},{al}-dimetil-bencenoacético (bilastina). Esta invención también se refiere a procedimientos para su preparación, composiciones farmacéuticas que las contienen y su uso para el tratamiento de reacciones alérgicas y de procesos patológicos mediados por la histamina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201531103 | 2015-07-24 | ||
ESP201531103 | 2015-07-24 | ||
PCT/ES2016/070560 WO2017017301A1 (es) | 2015-07-24 | 2016-07-22 | Formas cristalinas de bilastina y procedimientos para su preparación |
Publications (4)
Publication Number | Publication Date |
---|---|
ES2600827A1 ES2600827A1 (es) | 2017-02-10 |
ES2600827A8 true ES2600827A8 (es) | 2017-06-15 |
ES2600827B1 ES2600827B1 (es) | 2017-11-24 |
ES2600827B9 ES2600827B9 (es) | 2018-03-28 |
Family
ID=57884122
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES201690068A Active ES2600827B9 (es) | 2015-07-24 | 2016-07-22 | Formas cristalinas de bilastina y procedimientos para su preparación |
ES16829901T Active ES2874577T3 (es) | 2015-07-24 | 2016-07-22 | Formas cristalinas de bilastina y procedimientos para su preparación |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES16829901T Active ES2874577T3 (es) | 2015-07-24 | 2016-07-22 | Formas cristalinas de bilastina y procedimientos para su preparación |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP3327012B1 (es) |
JP (1) | JP7168447B2 (es) |
KR (1) | KR102657147B1 (es) |
CN (1) | CN107849007A (es) |
CA (1) | CA2993134A1 (es) |
CY (1) | CY1124505T1 (es) |
ES (2) | ES2600827B9 (es) |
LT (1) | LT3327012T (es) |
MX (1) | MX2018000883A (es) |
PL (1) | PL3327012T3 (es) |
PT (1) | PT3327012T (es) |
SI (1) | SI3327012T1 (es) |
WO (1) | WO2017017301A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3452462A4 (en) * | 2016-05-05 | 2019-10-23 | MSN Laboratories Private Limited, R&D Center | SOLID STATE FORMS OF 2- [4- (2- {4- [1- (2-ETHOXYETHYL) -1H-BENZIMIDAZOL-2-YL] -1-PIPERIDINYL} ETHYL) PHENYL] -2-METHYLPROPANOIC ACID AND PREPARATION METHOD THEREOF |
EP3453384B1 (en) | 2017-09-07 | 2020-05-27 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising bilastine |
EP3641735B1 (en) | 2017-12-18 | 2021-02-24 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising bilastine form 3 and a water-soluble filler |
ES2835287T3 (es) | 2017-12-18 | 2021-06-22 | Tiefenbacher Alfred E Gmbh & Co Kg | Composición farmacéutica de comprimido que comprende la forma polimórfica 3 de bilastina y aluminometasilicato de magnesio |
WO2020065475A1 (en) * | 2018-09-25 | 2020-04-02 | Glenmark Life Sciences Limited; Glenmark Pharmaceuticals Limited | Title: process for the preparation of bilastine |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2124167B1 (es) * | 1996-06-04 | 1999-09-16 | Espanola Prod Quimicos | Nuevos derivados del bencimidazol con actividad antihistaminica. |
HU230032B1 (hu) * | 2002-04-19 | 2015-05-28 | Faes Farma, S.A | Polimorf 4-{2-[4-[1-(2-etoxietil)-1H-benzimidazol-2-il]-1-piperidinil]etil}-alfa,alfa-dimetil-benzenoecetsav |
CZ307500B6 (cs) * | 2012-08-15 | 2018-10-24 | Zentiva, K.S. | Způsob přípravy derivátu 2-methyl-2´-fenylpropionové kyseliny využívající nové intermediáty |
CN103214454A (zh) * | 2013-03-30 | 2013-07-24 | 北京万全德众医药生物技术有限公司 | 一种比拉斯汀晶型及制备方法 |
CN104447682A (zh) * | 2013-09-12 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 比拉斯汀化合物 |
CN104447683A (zh) * | 2013-09-12 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 一种稳定的比拉斯汀化合物 |
SK7066Y1 (sk) * | 2014-01-29 | 2015-03-03 | Zentiva Ks | Kryštalický dihydrát bilastínu |
CN103788062A (zh) * | 2014-02-17 | 2014-05-14 | 北京博泽德润医药科技开发有限公司 | 一种比拉斯汀晶型及其制备方法 |
CN104151290A (zh) * | 2014-06-30 | 2014-11-19 | 北京万全德众医药生物技术有限公司 | 一种制备比拉斯汀新晶型的方法 |
CN104177331B (zh) * | 2014-09-10 | 2016-08-17 | 北京科莱博医药开发有限责任公司 | 比拉斯汀的制备方法 |
CN104530002B (zh) * | 2015-01-29 | 2017-06-09 | 天津梅花生物医药科技有限公司 | 比拉斯汀化合物及其制备方法 |
-
2016
- 2016-07-22 CN CN201680042950.8A patent/CN107849007A/zh active Pending
- 2016-07-22 EP EP16829901.4A patent/EP3327012B1/en active Active
- 2016-07-22 SI SI201631236T patent/SI3327012T1/sl unknown
- 2016-07-22 ES ES201690068A patent/ES2600827B9/es active Active
- 2016-07-22 CA CA2993134A patent/CA2993134A1/en active Pending
- 2016-07-22 MX MX2018000883A patent/MX2018000883A/es unknown
- 2016-07-22 JP JP2018522878A patent/JP7168447B2/ja active Active
- 2016-07-22 PL PL16829901T patent/PL3327012T3/pl unknown
- 2016-07-22 ES ES16829901T patent/ES2874577T3/es active Active
- 2016-07-22 WO PCT/ES2016/070560 patent/WO2017017301A1/es active Application Filing
- 2016-07-22 LT LTEP16829901.4T patent/LT3327012T/lt unknown
- 2016-07-22 PT PT168299014T patent/PT3327012T/pt unknown
- 2016-07-22 KR KR1020187003411A patent/KR102657147B1/ko active IP Right Grant
-
2021
- 2021-06-16 CY CY20211100536T patent/CY1124505T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2874577T3 (es) | 2021-11-05 |
WO2017017301A1 (es) | 2017-02-02 |
ES2600827B1 (es) | 2017-11-24 |
EP3327012B1 (en) | 2021-03-17 |
SI3327012T1 (sl) | 2021-10-29 |
PL3327012T3 (pl) | 2021-11-22 |
CA2993134A1 (en) | 2017-02-02 |
KR20180036722A (ko) | 2018-04-09 |
CY1124505T1 (el) | 2022-07-22 |
JP2018522945A (ja) | 2018-08-16 |
JP7168447B2 (ja) | 2022-11-09 |
BR112018001225A2 (pt) | 2018-09-11 |
LT3327012T (lt) | 2021-09-10 |
ES2600827A1 (es) | 2017-02-10 |
PT3327012T (pt) | 2021-06-21 |
MX2018000883A (es) | 2018-08-15 |
RU2018104258A3 (es) | 2019-12-25 |
EP3327012A1 (en) | 2018-05-30 |
EP3327012A4 (en) | 2018-12-19 |
KR102657147B1 (ko) | 2024-04-12 |
CN107849007A (zh) | 2018-03-27 |
ES2600827B9 (es) | 2018-03-28 |
RU2018104258A (ru) | 2019-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2600827A8 (es) | Formas cristalinas de bilastina y procedimientos para su preparación | |
CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
CL2017002650A1 (es) | Compuestos novedosos | |
AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
PE20170300A1 (es) | Procesos para preparar un inhibidor de jak 1 y nuevas formas de este | |
CL2016000424A1 (es) | Métodos y composiciones para el arn-guiado tratamiento de la infección por vih | |
CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
CL2015000880A1 (es) | Compuestos heterociclicos derivados de 4-pirimidinona, inhibidores de la transcriptasa inversa del vih; composicion farmaceutica; uso en la profilaxis o el tratamiento de infeccion por vih o para la profilaxis, tratamiento o retraso de la aparicion del sida en un sujeto. | |
CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
CL2014000311A1 (es) | Compuestos derivados de benzotiazepinas sustituidas; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis de la infeccion del virus sincicial respiratorio. | |
CR20160222U (es) | Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas | |
CL2014000630A1 (es) | Una composicion que comprende 1) un compuesto derivado de nucleosido denominado como compuesto 10 y 2) un compuesto derivado de acido 5-tiofeno-2-carboxilico denominado como compuesto 5 o un compuesto derivado del ester metilico del acido carbamico denominado como compuesto 6; y su uso para el tratamiento profilactico o terapeutico de una infeccion por vhc. | |
CO6791571A2 (es) | Moduladores de la proteína tirosina quinasa 7 (ptk7) para el tratamiento diagnóstico o profilaxis de trastornos neoplásicos | |
CR20140200A (es) | Formas solidas de 3-(5-amino-2-metil-4-oxo-ah-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos | |
CL2015001724A1 (es) | Compuestos derivados de péptidos, agonistas de oxitocina; composicion farmaceutica; y su uso para en el tratamiento del autismo, estres, ansiedad, depresion, esquizofrenia,entre otros. | |
CL2017002082A1 (es) | Nuevas proteínas especificas para pioverdina y pioquelina | |
BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
GT201700163A (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd) | |
AR092188A1 (es) | ANTICUERPOS HUMANOS PARA GFRa3 Y METODOS PARA SU USO | |
DOP2016000253A (es) | Nuevos compuestos | |
CO2018001840A2 (es) | Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5 | |
BR112018014590A2 (pt) | formulações/composições compreendendo um inibidor de btk | |
UY36145A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
CL2014002929A1 (es) | Composicion que comprende ácido poliinosínico - policitidílico (poli (i:c) ) y un polimero portador; y sus usos para el tratamiento de infecciones de las vías respiratorias altas. | |
BR112017011304A2 (pt) | Processo para a preparação de ésteres de ácido láctico e ácido 2-hidroxi-3-butenoico ou alfa- hidroxi-análogos de metionina a partir de açúcares |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 2600827 Country of ref document: ES Kind code of ref document: B1 Effective date: 20171124 |